The United States is the largest pharmaceutical market in the world, and Taiwan's biopharmaceutical companies are boosting their competitiveness there through factory setups and production line expansions. In recent years, Taiwan's biopharma sector has been increasingly engaging with the U.S. market, particularly under the tariffs policies of former President Trump.

Porumaha Pharmaceutical (6472) announced plans to acquire three pharmaceutical companies in the U.S. in 2024, including Upsher-Smith Laboratories in Minnesota, a sterile injection manufacturing plant from Emergen BioSolutions, and Pyros based in New Jersey. Additionally, by investing in Taifeng Biotech, they aim to enhance their protein production facility in the U.S.

Moreover, Yongxin Holding (3705) has been expanding production lines at its Carlsbad Technology subsidiary in California, with plans to double production capacity within the next two years.

Shengda (1720) has successfully acquired the U.S. company Magnifica, gaining production access at the TULEX factory in New Jersey, attracting more pharmaceutical collaborations. Additionally, innovative medical materials company Yian (6499) is also looking to expand its U.S. production base, highlighting the importance of the North American market to Taiwan's biopharma industry.